Plus therapeutics to present respect™-gbm clinical trial data at the 2021 sno annual meeting

Austin, texas, sept. 30, 2021 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a u.s. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present interim data on rhenium-186 nanoliposome (186rnl) from its respect™ phase 1 clinical trial in recurrent glioblastoma (gbm) at the 2021 society for neuro-oncology (sno) annual meeting and education day being held november 18-21, 2021 in boston, massachusetts.
pstv Ratings Summary
pstv Quant Ranking